Last reviewed · How we verify
NCT05840861
Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders
trial testing Vortioxetine in Major Depressive Disorder in 59 participants. Status unknown.
21 August 2023
Quick facts
| Lead sponsor | Central South University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 59 |
| Start date | 5 November 2020 |
| Primary completion | 21 August 2023 |
| Estimated completion | 5 September 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Vortioxetine (vortioxetine) — full drug profile →
- Quetiapine (quetiapine) — full drug profile →
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
- Bipolar Disorder — all drugs for Bipolar Disorder →
Sponsor
Central South University
Who can join
Adults 18 to 35, any sex, with Major Depressive Disorder or Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability and clinical symptoms in patients with MDD and bipolar disorder(BD) after two months of vortioxetine treatment. The investigators hypothesized that patients with MDD and BP have abnormal mGluR5 availability in certain brain regions, and baseline mGLUR5 availability can predict prognosis the prognosis of MDD and BD. fMRI and NODDI are also used to evaluate the function or neurite condition at baseline and 8 week
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05840861
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vortioxetine
Trials testing the same drug.
- NCT07266545 — RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) · Phase 4 · recruiting
- NCT06604520 — Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia · Phase 2 · recruiting
- NCT05814640 — Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) · Phase 1, PHASE2 · recruiting
- NCT04446039 — Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea · completed
- NCT05481957 — Vortioxetine Adjunctive Treatment in Bipolar Depression · Phase 4 · completed
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other Central South University trials
Trials by the same sponsor.
- NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
- NCT07446478 — TIS for Improving Cognitive Impairment Associated With Schizophrenia · NA · not yet recruiting
- NCT07045142 — Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients · Phase 3 · recruiting
- NCT07066813 — Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces · recruiting
- NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05840861 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central South University
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05840861.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing